Charles Schwab
BIOR

Charles Schwab’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Charles Schwab’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-180
Closed -$22K – 3585
2022
Q3 		$22K Hold
180
– – ﹤0.01% 3475
2022
Q2 		$32K Hold
180
– – ﹤0.01% 3462
2022
Q1 		$53K Hold
180
– – ﹤0.01% 3522
2021
Q4 		$95K Buy
+180
New +$129K ﹤0.01% 3442
2021
Q2 		– Sell
-191
Closed -$228K – 3583
2021
Q1 		$228K Buy
+191
New +$263K ﹤0.01% 3302

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Charles Schwab's BIOR Position: Q4 2022 in Review

Charles Schwab sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2022, closing a stake of 180 shares — an estimated $22K sold.

Charles Schwab first reported a position in BIOR in Q1 2021 and held it in 5 quarters. The position peaked at $228K in Q1 2021. 42 funds tracked by Wall St. Rank hold BIOR as of Q4 2022.

  • Charles Schwab reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Charles Schwab sold 180 Biora Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $22K.
  • Charles Schwab first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Charles Schwab's Biora Therapeutics, Inc. Common Stock position peaked at $228K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.